Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial).
暂无分享，去创建一个
P. Armstrong | F. Van de Werf | H. White | K. Mahaffey | L. Wallentin | Zhen Huang | M. Valgimigli | R. Harrington | P. Aylward | D. Moliterno | Á. Cequier | Y. Lokhnygina | P. Tricoci | S. Leonardi | P. Widimsky | J. Strony | E. Chen
[1] Marc P. Bonaca,et al. Vorapaxar in the secondary prevention of atherothrombotic events. , 2012, The New England journal of medicine.
[2] Giuseppe Ambrosio,et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. , 2012, The New England journal of medicine.
[3] C. Held,et al. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. , 2009, American heart journal.
[4] Colin Baigent,et al. Low-dose aspirin for the prevention of atherothrombosis. , 2005, The New England journal of medicine.
[5] S. Yusuf,et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.
[6] B. Payrastre,et al. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase. , 1999, Blood.